We are hematooncologists, in the field of pathogenesis of Myelodysplastic Syndromes and Multiple Myeloma and especially focus on their therapeutic intervention. Specifically, we are concerned with the importance of coordinating genetic and epigenetic links in the emergence and development of therapeutic resistance. In addition to OMICs technologies and the development of PDX models for cancer research, we are also creating various transgenic mouse models.